GlassScriptPhysician profile
Robert A Schamberger
NPI 1003816844
$10,218.82
in general payments reported to CMS, 2019-2025
34 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,406 · 2020: $739 · 2021: $738 · 2022: $1,127 · 2023: $1,823 · 2024: $1,838 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,208.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,500.31 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $1,599.00 | 2019-2024 | Spravato, Xarelto |
| Abbvie INC. | $1,414.74 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $739.95 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $705.92 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $542.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $365.92 | 2023-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $360.56 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $264.44 | 2022-2025 | Mounjaro, Jardiance, Kisunla |
| Allergan, INC. | $186.25 | 2019-2020 | |
| Dexcom, INC. | $185.96 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $153.73 | 2025 | |
| Abbott Laboratories | $153.21 | 2022-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $138.81 | 2023 | Rexulti |
| Pfizer INC. | $135.63 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $131.87 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.66 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $68.66 | 2023-2025 | Acthar |
| Exact Sciences Corporation | $63.02 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $49.39 | 2025 | Korlym |
| Lundbeck LLC | $48.36 | 2025 | Rexulti |
| Eisai INC. | $47.18 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.05 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $39.90 | 2022-2023 | |
| Astellas Pharma US INC | $25.58 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $24.17 | 2022 | |
| Radius Health, INC. | $21.13 | 2021 | |
| Cequr Corporation | $19.84 | 2025 | Cequr Simplicity |
| Photonicare INC | $16.80 | 2025 | Otosight Middle Ear Scope |
| Gilead Sciences, INC. | $15.74 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.44 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.02 | 2024 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $14.17 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $13.63 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schamberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.